Todays approval provides an important new treatment option which can now help the millions of people in Europe living with symptomatic chronic heart failure with reduced ejection fraction said Faiez Zannad, M.D., Ph.D., EMPEROR Program clinical investigator and Emeritus Professor of Therapeutics at the University of Lorraine, France. New treatment options such as empagliflozin can save lives and help people spend less time in the hospital and more time with their families.
- Read more about Empagliflozin approved in Europe for the treatment of heart failure
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/empagliflozin-approved-in-europe-for-the-treatment-of-heart-failure
No comments:
Post a Comment